查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1869914

高血钾药物市场规模、份额和趋势分析报告：按药物类别、分销管道、地区和细分市场预测（2025-2033 年）

Hyperkalemia Drugs Market Size, Share & Trends Analysis Report By Drug Class (Novel Oral Potassium Binders), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

高血钾药物市场摘要

2024年全球高血钾药物市场规模估计为12.3亿美元，预计2033年将达38.7亿美元。

预计从 2025 年到 2033 年，该市场将以 13.8% 的复合年增长率成长。推动市场成长的主要因素是人口老化、慢性病（如慢性肾臟病(CKD) 和心臟衰竭）以及糖尿病等合併症的增加。

慢性肾臟病(CKD)、心臟衰竭、糖尿病以及其他导致血钾水平升高的疾病的日益普遍，推动了对有效高钾血症治疗方法的需求。例如，据报道，全球约有 5.89 亿 20 至 79 岁的成年人患有糖尿病。预计到 2050 年，这一数字将增至 8.53 亿。值得注意的是，超过 81% 的糖尿病患者居住在中低收入国家。製药公司正致力于开发和提供创新疗法来应对这种疾病。 2025 年 9 月，Astra Zeneca製药印度公司获得了印度中央药品标准控制组织 (CDSCO) 下属专家委员会 (SEC) 的批准，将在印度开展其高钾血症核准——环硅酸锆钠（Lokelma，一种口服混悬剂）的 IV 期临床试验。该研究将评估该药物在治疗成人高血钾症方面的安全性和有效性，以满足该地区重要的心血管和肾臟健康需求。

随着世界人口老化，老年族群越来越容易罹患心血管疾病、慢性肾臟病和糖尿病等慢性疾病，这些疾病会增加高血钾症的风险。这推动了对高血钾药物的需求，进而促进了药物创新和治疗方案的扩展。口服钾结合剂的进步和诊断能力的提升有助于更好地管理高血钾症，而策略合作和市场拓展则有助于提高全球药物的可及性。

目录

第一章调查方法和范围

第二章执行摘要

3. 高血钾药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 高血钾药物市场分析工具
    • 产业分析—波特五力分析
    • PESTEL 分析
  • 高血钾药物市场：研发管线分析

第四章 高血钾药物市场：药物类别估算与趋势分析

  • 药物类别细分仪表板
  • 高血钾药物市场：药物类别波动分析
  • 全球高血钾药物市场规模及趋势分析（依药物类别划分，2021-2033 年）
  • 一种新型口服钾粘合剂
  • 常规阳离子交换树脂
  • 其他的

第五章 高血钾药物市场：通路估算与趋势分析

  • 分销通路细分仪表板
  • 高血钾药物市场：通路波动分析
  • 全球高血钾药物市场规模及趋势分析（依通路划分，2021-2033 年）
  • 医院药房
  • 零售药房
  • 网路药房

第六章 高血钾药物市场：区域估算与趋势分析

  • 区域市场概览
  • 2024 年及 2033 年区域市占率分析
  • 高血钾药物市场区域概览：要点
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争情势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商概况
  • 公司简介
    • AstraZeneca plc
    • CSL Vifor（Vifor Pharma AG）
    • Sanofi
    • Kowa Company, Ltd.
    • KVK-Tech, Inc.
    • Fresenius Kabi AG
    • Novo Nordisk A/S
Product Code: GVR-4-68040-784-2

Hyperkalemia Drugs Market Summary

The global hyperkalemia drugs market size was estimated at USD 1.23 billion in 2024 and is projected to reach USD 3.87 billion by 2033, growing at a CAGR of 13.8% from 2025 to 2033. The market growth is primarily driven by an aging population, increasing prevalence of chronic diseases like chronic kidney disease (CKD) and heart failure, and comorbidities such as diabetes.

The increasing prevalence of chronic kidney disease (CKD), heart failure, diabetes, and other medical conditions that contribute to elevated potassium levels in the blood is driving demand for effective hyperkalemia treatments. For instance, approximately 589 million adults aged 20-79 were reported to have diabetes globally. Projections indicated this figure would rise to 853 million by 2050. Notably, over 81% of affected adults resided in low and middle-income countries. Pharmaceutical companies focus on developing and delivering innovative therapeutic solutions to address this condition. In September 2025, AstraZeneca Pharma India received approval from the Subject Expert Committee(SEC), operating under the Central Drug Standard Control Organisation (CDSCO), to conduct a Phase-IV clinical trial of Sodium Zirconium Cyclosilicate (Lokelma) powder for oral suspension used to treat hyperkalemia in India. This trial will evaluate safety and efficacy for managing elevated potassium levels in adult patients, addressing critical cardiovascular and renal health needs in the region.

Aging global population, marked by a growing elderly segment, faces increased vulnerability to chronic conditions such as cardiovascular disease, chronic kidney disease, and diabetes, which elevate hyperkalemia risk. This is expected to drive the demand for hyperkalemia drugs, fostering pharmaceutical innovation and expanded treatment options. Advances in oral potassium binders and improved diagnostic capabilities support better management, while strategic collaborations and market expansion enhance drug accessibility worldwide.

Global Hyperkalemia Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hyperkalemia drugs market report based on drug class, distribution channel, and region:

  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Novel Oral Potassium Binders
  • Traditional Cation-Exchange Resins
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Distribution Channel
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class Outlook
    • 2.2.2. Distribution Channel Outlook
    • 2.2.3. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Hyperkalemia Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Hyperkalemia drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Hyperkalemia Drugs Market: Pipeline Analysis

Chapter 4. Hyperkalemia Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Segment Dashboard
  • 4.2. Hyperkalemia Drugs Market: Drug Class Movement Analysis
  • 4.3. Global Hyperkalemia Drugs Market Size & Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 4.4. Novel Oral Potassium Binders
    • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Traditional Cation-Exchange Resins
    • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Hyperkalemia Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Distribution Channel Segment Dashboard
  • 5.2. Hyperkalemia Drugs Market: Distribution Channel Movement Analysis
  • 5.3. Global Hyperkalemia Drugs Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Online Pharmacies
    • 5.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Hyperkalemia Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2033
  • 6.3. Hyperkalemia Drugs Market by Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. Mexico
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. UK
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.2. Germany
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.3. France
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.4. Italy
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.6. Norway
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework/ reimbursement structure
      • 6.5.7.3. Competitive scenario
      • 6.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key country dynamics
      • 6.5.8.2. Regulatory framework/ reimbursement structure
      • 6.5.8.3. Competitive scenario
      • 6.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.4. Australia
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.6. Thailand
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.2. Argentina
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.3. UAE
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key country dynamics
      • 6.8.4.2. Regulatory framework/ reimbursement structure
      • 6.8.4.3. Competitive scenario
      • 6.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company heat map analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. AstraZeneca plc
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. CSL Vifor (Vifor Pharma AG)
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Sanofi
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Kowa Company, Ltd.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. KVK-Tech, Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Fresenius Kabi AG
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Novo Nordisk A/S
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global hyperkalemia drugs market, by region, 2021 - 2033 (USD Million)
  • Table 3 Global hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 4 Global hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 5 North America hyperkalemia drugs market, by country, 2021 - 2033 (USD Million)
  • Table 6 North America hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 7 North America hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 8 U.S. hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 9 U.S. hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 10 Canada hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 11 Canada hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 12 Mexico hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 13 Mexico hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Europe hyperkalemia drugs market, by Country, 2021 - 2033 (USD Million)
  • Table 15 Europe hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 16 Europe hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Germany hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 18 Germany hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 19 UK hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 20 UK hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 21 France hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 22 France hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 23 Italy hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 24 Italy hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 25 Spain hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 26 Spain hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Denmark hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 28 Denmark hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 29 Sweden hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 30 Sweden hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 31 Norway hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 32 Norway hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Asia Pacific hyperkalemia drugs market, by Country, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 China hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 37 China hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 38 Japan hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 39 Japan hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 40 India hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 41 India hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 South Korea hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 43 South Korea hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 44 Australia hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 45 Australia hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 46 Thailand hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 47 Thailand hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Latin America hyperkalemia drugs market, by Country, 2021 - 2033 (USD Million)
  • Table 49 Latin America hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 50 Latin America hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 51 Brazil hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 52 Brazil hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 53 Argentina hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 54 Argentina hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 Middle East & Africa hyperkalemia drugs market, by Country, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 South Africa hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 59 South Korea hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 60 Saudi Arabia hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 62 UAE hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 63 UAE hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 Kuwait hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 65 Kuwait hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market snapshot
  • Fig. 8 Hyperkalemia drugs market segmentation
  • Fig. 9 Market Snapshot
  • Fig. 10 Therapeutic approach and disease outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Hyperkalemia drugs market dynamics
  • Fig. 13 Hyperkalemia drugs market: Porter's five forces analysis
  • Fig. 14 Hyperkalemia drugs market: PESTLE analysis
  • Fig. 15 Drug class market, 2021 - 2033 (USD Million)
  • Fig. 16 Novel oral potassium binders market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 Traditional Cation-Exchange Resins market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 18 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 20 Hospital Pharmacies market estimates and forecast, 2021 - 2033
  • Fig. 21 Retail Pharmacies market estimates and forecast, 2021 - 2033
  • Fig. 22 Online Pharmacies market estimates and forecast, 2021 - 2033
  • Fig. 23 Hyperkalemia drugs market revenue, by region
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 North America hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. country dynamics
  • Fig. 27 U.S. hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 28 Canada country dynamics
  • Fig. 29 Canada hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 30 Mexico country dynamics
  • Fig. 31 Mexico hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 32 Europe hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 33 UK country dynamics
  • Fig. 34 UK hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 35 Germany country dynamics
  • Fig. 36 Germany hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 37 France country dynamics
  • Fig. 38 France hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 39 Italy country dynamics
  • Fig. 40 Italy hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 41 Spain country dynamics
  • Fig. 42 Spain hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 43 Norway country dynamics
  • Fig. 44 Norway hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 45 Sweden country dynamics
  • Fig. 46 Sweden hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 47 Denmark country dynamics
  • Fig. 48 Denmark hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan country dynamics
  • Fig. 51 Japan hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 52 China country dynamics
  • Fig. 53 China hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 54 India country dynamics
  • Fig. 55 India hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 56 Australia country dynamics
  • Fig. 57 Australia hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 58 South Korea country dynamics
  • Fig. 59 South Korea hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 60 Thailand country dynamics
  • Fig. 61 Thailand hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 62 Latin America hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 63 Brazil country dynamics
  • Fig. 64 Brazil hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 65 Argentina country dynamics
  • Fig. 66 Argentina hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 67 MEA hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 68 South Africa country dynamics
  • Fig. 69 South Africa hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 70 Saudi Arabia country dynamics
  • Fig. 71 Saudi Arabia hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 72 UAE country dynamics
  • Fig. 73 UAE hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 74 Kuwait country dynamics
  • Fig. 75 Kuwait hyperkalemia drugs market, 2021 - 2033 (USD Million)
  • Fig. 76 Company categorization
  • Fig. 77 Company market position analysis
  • Fig. 78 Strategic framework